Within the biotech sector, the spinal cord injury (SCI) segment stands out as an enormous market with significant unmet needs. The World Health Organization estimates between 250,000 and 500,000 people around the world suffer from SCI each year. It’s also been estimated that around 291,000 people in the US currently live with an SCI, while the European SCI population is up to 500,000 people. read more